ASH 2017 Conference Coverage
World Myeloma Forum Expert Panel members Sagar Lonial, MD; Suzanne Lentzsch, MD, PhD; Ravi Vij, MD, MBA; and Ola Landgren, MD, PhD discuss data presented at ASH 2017.
- CAR T-Cell Therapy in Multiple Myeloma
- Novel Therapies Multiple Myeloma
- Newly Diagnosed Multiple Myeloma
- Relapsed and Refractory Multiple Myeloma
- Smoldering Multiple Myeloma
- Novel Administration of Daratumumab
Rafael Fonseca, MD discusses:
Abstract 904: Minimal Residual Disease in the Maintenance Setting in Myeloma: Prognostic Significance and Impact of Lenalidomide.
Abstract 401: Double Autologous Stem Cell Transplantation Significantly Prolongs Progression-Free Survival and Overall Survival in Comparison with Single Autotransplantation in Newly Diagnosed Multiple Myeloma: An Analysis of Phase 3 EMN02/HO95 Study.
Xavier Leleu, MD discusses:
Abstract 398: First report of the IFM 2014-02 randomized open label phase 3 trial of 2 conditioning regimen, HDM 200 versus Bortezomib +HDM 200.
Abstract 739: Update of the POLLUX phase 3 randomized open label international trial of Daratumumab plus lenalidomide and dexamethasone, versus the doublet control arm lenalidomide and dexamethasone.
Ravi Vi, MD discusses:
Abstract 392: Next Generation Sequencing Identifies Smoldering Multiple Myeloma Patients with a High Risk of Disease Progression.
Abstract 740: Durable Clinical Responses in Heavily Pretreated Patients with Relapsed/Refractory Multiple Myeloma: Updated Results from a Multicenter Study of bb2121 Anti-Bcma CAR T Cell Therapy.
Wee Joo Chng, MD discusses:
Abstract 839: Genomic Predictors of Progression-Free Survival Among Patients.with Relapsed or Refractory Multiple Myeloma Treated with Carfilzomib and Dexamethasone or Bortezomib and Dexamethasone in the Phase 3 Endeavor Trial.
Abstract 436: Lenalidomide Maintenance Significantly Improves Outcomes Compared to Observation Irrespective of Cytogenetic Risk: Results of the Myeloma XI Trial.